Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Iaso Therapeutics, Inc. secured a $299,999 NIH SBIR/STTR award: Next generation multi-antigen Staphylococcus aureus vaccine enabled by proprietary mutant bacteriophage Qbeta
Amount Raised
$300,000
Round Type
Grant
East LansingBiotechnologyInvestors
Description
Project summary Vaccines have saved millions of lives. However, there are many diseases against which vaccines are not yet available, with the COVID-19 pandemic in the world serving as a painful reminder of the need for vaccines against emerging diseases. With the growing emphasis on vaccine safety, next-generation vaccine designs have been increasingly focusing on subunit antigens. Because subunit epitopes tend to have lower immunogenicity, immunogenic carriers are critical to deliver the desi
Related People
Funding Insights
Based on industry dataWatching Iaso Therapeutics? See every signal — funding, hires, M&A, contracts, sentiment.
Book a demoChoose your plan